Recurrent pembrolizumab-induced mechanical small bowel obstruction in a patient with metastatic cervical cancer

Recurrent pembrolizumab-induced mechanical small bowel obstruction in a patient with metastatic cervical cancer

Bibliographic Details
Main Authors:	Sha Sha, Evan R. J. Goyette, Loyd A. West, Jessica L. Bentz
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Gynecologic Oncology Reports
Subjects:	Pembrolizumab Cervical cancer Recurrent small bowel obstruction Checkpoint immunotherapy Immune-mediated adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578924000614

Similar Items

Severe gastritis due to pembrolizumab treatment in a lung cancer patient
by: Noriko Hayama, et al.
Published: (2020-10-01)

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer
by: Xue Zhang, et al.
Published: (2024-12-01)

Unusual gingival presentation following treatment with pembrolizumab
by: Annu Singh, et al.
Published: (2024-03-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
by: Yanxin Liu, et al.
Published: (2023-03-01)

Immunotherapy in patients with cervical cancer
by: A. G. Kedrova
Published: (2020-11-01)

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
by: Ying-tao Lin, et al.
Published: (2024-01-01)

Case report: Clinical experience of treating pembrolizumab-induced systemic capillary leak syndrome (SCLS) in one patient with metastatic gastroesophageal junction squamous cell carcinoma
by: Hua Ni, et al.
Published: (2023-09-01)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
by: Fanny Zulay Acero Brand, et al.
Published: (2018-03-01)

Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature
by: R. Saad, et al.
Published: (2024-02-01)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
by: Soo Yeon Jang, et al.
Published: (2022-09-01)

Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers
by: Chien-Hsiang Kao, et al.
Published: (2024-04-01)

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report
by: Tomoya Harada, et al.
Published: (2024-01-01)

Pembrolizumab-induced myasthenia gravis: Two patients’ experiences
by: Leslie Montag, et al.
Published: (2024-08-01)

Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission
by: Giuseppe Civardi, et al.
Published: (2024-04-01)

Hepatic sinusoidal obstruction syndrome (SOS) associated with checkpoint inhibitor therapy
by: Marianna Litterio, et al.
Published: (2024-12-01)

Anterior Uveitis Secondary to Avelumab and Pembrolizumab in a Patient with Metastatic Renal Cell Carcinoma—A Case Report
by: Wei-Lun Chu, et al.
Published: (2024-03-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Eosinophilic fasciitis as an immune-related adverse event of Pembrolizumab in Hodgkin’s lymphoma: a case report
by: Kamil Khan, et al.
Published: (2024-06-01)

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
by: Bradley J. Monk, et al.
Published: (2024-11-01)

Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
by: Ioannis Kournoutas, et al.
Published: (2024-02-01)

Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Primary cervical malignant melanoma that was successfully treated with pembrolizumab: a case report and literature review
by: Mengpei Zhang, et al.
Published: (2024-06-01)

Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy
by: Ian Liang, et al.
Published: (2023-03-01)

Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review
by: Chongya Zhai, et al.
Published: (2024-01-01)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
by: Hideki Terai, MD, et al.
Published: (2022-11-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)
by: Szu-Ting Yang, et al.
Published: (2024-09-01)

Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System
by: Stefan Milutinovic, et al.
Published: (2024-10-01)

Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report
by: João Grilo, et al.
Published: (2023-06-01)

Interstitial nephritis secondary to treatment with pembrolizumab, a rare complication in two patients with lung adenocarcinoma
by: Diana Alexandra Gonçalves Pimenta, et al.
Published: (2022-07-01)

Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab
by: F.M. Perrotta, et al.
Published: (2020-11-01)

A Case of Metastatic Melanoma Presenting as a Small Bowel Obstruction
by: Danielle Harris, et al.
Published: (2022-07-01)

Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint‐inhibitor pneumonitis: A case report and literature review
by: Deepak Rajendran Nair, et al.
Published: (2023-07-01)

Case Report: Immune Checkpoint Inhibitors as a Single Agent in the Treatment of Metastatic Cervical Cancer
by: Manasa Anipindi, et al.
Published: (2022-04-01)

mechanical small bowel obstruction
by: munthir Al-Obaidi
Published: (2007-01-01)

Discrepancy in PD-L1 expression between primary and metastatic tumors in two patients with recurrent cervical cancer
by: Brittany File, et al.
Published: (2024-10-01)

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
by: Nikolaos Spathas, et al.
Published: (2018-09-01)

Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis
by: Lin Qi, et al.
Published: (2022-08-01)